BR0114986A - Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. - Google Patents
Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.Info
- Publication number
- BR0114986A BR0114986A BR0114986-5A BR0114986A BR0114986A BR 0114986 A BR0114986 A BR 0114986A BR 0114986 A BR0114986 A BR 0114986A BR 0114986 A BR0114986 A BR 0114986A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- substituted
- alkyl
- pharmaceutically acceptable
- hydrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/22—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/02—Compounds containing any of the groups, e.g. carbazates
- C07C281/04—Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cultivation Of Plants (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE PELO MENOS UM COMPOSTO OU UM SAL, SOLVATO OU HIDRATO DESTE FARMACEUTICAMENTE ACEITáVEIS, E, PROCESSO PARA PREPARAR TRIAZOLONA A PARTIR DE UMA ACIL SEMICARBAZIDA". A presente invenção está direcionada aos compostos representados pela seguinte fórmula estrutural e seus sais, solvatos e hidratos farmaceuticamente aceitáveis, R1 é um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 8~, aril-alquila C~ 0-2~, heteroaril-alquila C~ 0-2~, cicloalquilarila C~ 3~-C~ 6~ alquila C~ 0-2~ ou fenila. W é O ou S. R2 é H ou um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~ e heteroarila. X é um ligador de alquileno C~ 2~-C~ 5~ em que um átomo de carbono do ligador pode ser substituído com O, NH ou S. Y é C, O, S, NH ou uma ligação simples. Além disso, E é (CH~ 2~)~ n~COOH, em que n é 0, 1, 2 ou 3, ou C(R3)(R4)A, em que A é um grupo funcional ácido tal como carboxila, sulfonamida substituído ou não substituído por carboxamida ou tetrazol substituído ou não substituído. R3 é H, alquila C~ 1~-C~ 5~, alcóxi C~ 1~-C~ 5~ saturados ou insaturados. Adicionalmente, R4 é H, halo, um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 5~, alcóxi C~ 1~-C~ 5~, cicloalquila C~ 3~-C~ 6~, arilalquila C~ 0~-C~ 4~ e fenila ou R3 e R4 são combinados para formar um cicloalquila C~ 3~-C~ 4~.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24731700P | 2000-11-10 | 2000-11-10 | |
PCT/US2001/042928 WO2002038553A2 (en) | 2000-11-10 | 2001-11-09 | Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0114986A true BR0114986A (pt) | 2003-09-23 |
Family
ID=22934453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0114986-5A BR0114986A (pt) | 2000-11-10 | 2001-11-09 | Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. |
Country Status (35)
Country | Link |
---|---|
US (3) | US7304062B2 (pt) |
EP (1) | EP1335908B1 (pt) |
JP (1) | JP4243101B2 (pt) |
KR (1) | KR100839705B1 (pt) |
CN (1) | CN1479728A (pt) |
AR (1) | AR031305A1 (pt) |
AT (1) | ATE386026T1 (pt) |
AU (3) | AU2859202A (pt) |
BR (1) | BR0114986A (pt) |
CA (1) | CA2421154A1 (pt) |
CY (1) | CY1107388T1 (pt) |
CZ (1) | CZ20031283A3 (pt) |
DE (1) | DE60132799T2 (pt) |
DK (1) | DK1335908T3 (pt) |
EA (1) | EA006920B1 (pt) |
EC (1) | ECSP034595A (pt) |
ES (1) | ES2300378T3 (pt) |
HK (1) | HK1058790A1 (pt) |
HR (1) | HRP20030365A2 (pt) |
HU (1) | HUP0301655A2 (pt) |
IL (2) | IL154840A0 (pt) |
MX (1) | MXPA03004141A (pt) |
MY (1) | MY157884A (pt) |
NO (1) | NO20032059L (pt) |
NZ (1) | NZ524569A (pt) |
PE (1) | PE20020693A1 (pt) |
PL (1) | PL362692A1 (pt) |
PT (1) | PT1335908E (pt) |
SI (1) | SI1335908T1 (pt) |
SK (1) | SK5412003A3 (pt) |
SV (1) | SV2003000727A (pt) |
TW (1) | TW200716572A (pt) |
UA (1) | UA82048C2 (pt) |
WO (1) | WO2002038553A2 (pt) |
ZA (1) | ZA200302517B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002347985A1 (en) * | 2001-11-15 | 2003-06-10 | Eli Lilly And Company | Peroxisome proliferator activated receptor alpha agonists |
GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
AU2003241579B9 (en) | 2002-06-19 | 2009-07-30 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
FR2866339B1 (fr) * | 2004-02-18 | 2006-05-05 | Pf Medicament | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
US7262318B2 (en) | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
KR100803481B1 (ko) * | 2004-07-27 | 2008-02-14 | 에프. 호프만-라 로슈 아게 | 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물 |
US8293778B2 (en) | 2004-07-27 | 2012-10-23 | Roche Palo Alto Llc | Heterocyclic antiviral compounds |
WO2006010545A1 (en) | 2004-07-27 | 2006-02-02 | F. Hoffmann-La Roche Ag | Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors |
KR20070050475A (ko) * | 2004-08-11 | 2007-05-15 | 교린 세이야꾸 가부시키 가이샤 | 신규 환상 아미노 안식향산 유도체 |
WO2006068199A1 (ja) * | 2004-12-22 | 2006-06-29 | Mochida Pharmaceutical Co., Ltd. | 代謝的に安定な3-オキシ-1,2,4-トリアゾール誘導体 |
DOP2006000018A (es) * | 2005-01-28 | 2006-07-15 | Lilly Co Eli | Formulaciones y regimen de dosificación para moduladores alfa de ppar |
FR2882750B1 (fr) | 2005-03-03 | 2007-05-11 | Pierre Fabre Medicament Sa | Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine |
EP1862464A4 (en) * | 2005-03-23 | 2010-08-25 | Kyorin Seiyaku Kk | NEW CYCLIC AMINOPHENYL ALKANIC ACID DERIVATIVE |
CN101180280A (zh) * | 2005-03-24 | 2008-05-14 | 弗·哈夫曼-拉罗切有限公司 | 作为杂环逆转录酶抑制剂的1,2,4-三唑-5-酮化合物 |
WO2007126043A1 (ja) * | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
AU2008218841A1 (en) * | 2007-02-23 | 2008-08-28 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
CN101657433A (zh) | 2007-03-29 | 2010-02-24 | 弗·哈夫曼-拉罗切有限公司 | 非核苷逆转录酶抑制剂 |
WO2010002712A2 (en) * | 2008-06-30 | 2010-01-07 | 3M Innovative Properties Company | Method of crystallization |
CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
WO2010064633A1 (ja) | 2008-12-01 | 2010-06-10 | 田辺三菱製薬株式会社 | チアゾール環を含むカルボン酸誘導体およびその医薬用途 |
US8575430B2 (en) * | 2010-03-02 | 2013-11-05 | Nunhems, B.V. | Hybrid artichoke variety NUN 4006 AR |
US20110167512A1 (en) * | 2009-03-02 | 2011-07-07 | Nunhems B.V. | Hybrid artichoke variety nun 4006 ar |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
US20100245582A1 (en) * | 2009-03-25 | 2010-09-30 | Syclipse Technologies, Inc. | System and method of remote surveillance and applications therefor |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US8648233B2 (en) * | 2010-09-20 | 2014-02-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4021 AR |
US8669420B2 (en) | 2012-02-29 | 2014-03-11 | Nunhems B.V. | Hybrid artichoke variety NUN 4060 AR |
US9505728B2 (en) | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
MX2015007433A (es) * | 2012-12-20 | 2015-12-07 | Inception 2 Inc | Compuestos de triazolona y usos de los mismos. |
WO2015035059A1 (en) * | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
RU177130U1 (ru) * | 2017-11-29 | 2018-02-09 | Владимир Алексеевич Коннов | Плита изоляционная облицовочная |
CN115398657A (zh) | 2020-04-10 | 2022-11-25 | 松下知识产权经营株式会社 | 热电转换元件、热电转换组件、接合材料和热电转换元件的制造方法 |
CN112774869B (zh) * | 2020-12-25 | 2022-09-16 | 厦门紫金矿冶技术有限公司 | 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用 |
CN114853686B (zh) * | 2021-08-23 | 2023-06-20 | 中国药科大学 | 三氮唑酮类化合物及其医药用途 |
CN115894379A (zh) * | 2022-01-20 | 2023-04-04 | 中国药科大学 | 海因类化合物及其医药用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2090283A1 (en) | 1992-02-28 | 1993-08-29 | Nobuyuki Hamanaka | Phenoxyacetic acid derivatives |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
DE19517505A1 (de) * | 1995-05-12 | 1996-11-14 | Bayer Ag | Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten |
JPH11513382A (ja) | 1995-10-20 | 1999-11-16 | ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法 |
EP1028111B1 (en) * | 1997-10-17 | 2004-05-12 | Yamanouchi Pharmaceutical Co. Ltd. | Amide derivatives or salts thereof |
CN1208326C (zh) | 1998-04-23 | 2005-06-29 | 雷迪实验室有限公司 | 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物 |
GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
USPP14578P2 (en) * | 2002-09-23 | 2004-03-09 | Plant Sciences, Inc. | Artichoke plant named ‘PS-MSC0003’ |
-
2001
- 2001-09-11 UA UA2003054187A patent/UA82048C2/uk unknown
- 2001-11-07 AR ARP010105214A patent/AR031305A1/es unknown
- 2001-11-08 TW TW095138799A patent/TW200716572A/zh unknown
- 2001-11-08 MY MYPI20015155A patent/MY157884A/en unknown
- 2001-11-08 PE PE2001001108A patent/PE20020693A1/es not_active Application Discontinuation
- 2001-11-09 CN CNA018185878A patent/CN1479728A/zh active Pending
- 2001-11-09 CA CA002421154A patent/CA2421154A1/en not_active Abandoned
- 2001-11-09 BR BR0114986-5A patent/BR0114986A/pt not_active IP Right Cessation
- 2001-11-09 WO PCT/US2001/042928 patent/WO2002038553A2/en active IP Right Grant
- 2001-11-09 HU HU0301655A patent/HUP0301655A2/hu unknown
- 2001-11-09 DE DE60132799T patent/DE60132799T2/de not_active Expired - Fee Related
- 2001-11-09 SK SK541-2003A patent/SK5412003A3/sk not_active Application Discontinuation
- 2001-11-09 EP EP01989704A patent/EP1335908B1/en not_active Expired - Lifetime
- 2001-11-09 CZ CZ20031283A patent/CZ20031283A3/cs unknown
- 2001-11-09 PL PL01362692A patent/PL362692A1/xx unknown
- 2001-11-09 AU AU2859202A patent/AU2859202A/xx active Pending
- 2001-11-09 JP JP2002541088A patent/JP4243101B2/ja not_active Expired - Fee Related
- 2001-11-09 IL IL15484001A patent/IL154840A0/xx unknown
- 2001-11-09 SI SI200130828T patent/SI1335908T1/sl unknown
- 2001-11-09 EA EA200300558A patent/EA006920B1/ru not_active IP Right Cessation
- 2001-11-09 NZ NZ524569A patent/NZ524569A/en unknown
- 2001-11-09 MX MXPA03004141A patent/MXPA03004141A/es active IP Right Grant
- 2001-11-09 SV SV2001000727A patent/SV2003000727A/es not_active Application Discontinuation
- 2001-11-09 KR KR1020037006301A patent/KR100839705B1/ko not_active IP Right Cessation
- 2001-11-09 ES ES01989704T patent/ES2300378T3/es not_active Expired - Lifetime
- 2001-11-09 PT PT01989704T patent/PT1335908E/pt unknown
- 2001-11-09 DK DK01989704T patent/DK1335908T3/da active
- 2001-11-09 AT AT01989704T patent/ATE386026T1/de not_active IP Right Cessation
- 2001-11-09 AU AU2002228592A patent/AU2002228592B8/en not_active Ceased
- 2001-11-09 US US10/415,673 patent/US7304062B2/en not_active Expired - Fee Related
-
2003
- 2003-03-10 IL IL154840A patent/IL154840A/en active IP Right Grant
- 2003-03-31 ZA ZA200302517A patent/ZA200302517B/en unknown
- 2003-05-08 NO NO20032059A patent/NO20032059L/no unknown
- 2003-05-08 HR HR20030365A patent/HRP20030365A2/hr not_active Application Discontinuation
- 2003-05-08 EC EC2003004595A patent/ECSP034595A/es unknown
-
2004
- 2004-01-15 HK HK04100338A patent/HK1058790A1/xx not_active IP Right Cessation
-
2006
- 2006-06-29 AU AU2006202811A patent/AU2006202811A1/en not_active Abandoned
-
2007
- 2007-07-26 US US11/828,446 patent/US20090062358A1/en not_active Abandoned
-
2008
- 2008-04-10 CY CY20081100391T patent/CY1107388T1/el unknown
- 2008-06-27 US US12/215,466 patent/US7868225B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0114986A (pt) | Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. | |
AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
TW200716576A (en) | Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
BRPI0818193B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
BR0109011A (pt) | Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica | |
ES2188194T3 (es) | 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4. | |
HRP20090627T1 (hr) | Inhibitori hcv ns3 proteaze | |
HRP20020175B1 (en) | N-heterocyclikc derivatives as nos inhibitors | |
AR035548A1 (es) | Compuestos organicos | |
DE602004031258D1 (de) | Polycyclische mittel zur behandlung von infektione | |
PE20081583A1 (es) | Agentes antibacterianos derivados de compuestos carbonilamino | |
BR0315815A (pt) | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto | |
BRPI0608732A2 (pt) | composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto | |
NO20051051L (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme i terapeutiske midler | |
BRPI0414738A (pt) | derivados de ácido acético substituìdos | |
CA2421114A1 (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
BRPI0415220A (pt) | processo de produção de amida carboxìlica e derivados da mesma | |
TW200745104A (en) | Multikinase inhibitor | |
AU2003207432A1 (en) | Urea linker derivatives for use as ppar modulators | |
BRPI0409471B8 (pt) | processo para preparação de 2-cianopirrolidinas n-substituídas | |
CA2423007A1 (en) | Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients | |
AR046310A1 (es) | Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas. | |
BR0208823A (pt) | Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica | |
DE60125053D1 (de) | Cephem verbindungen und diese enthaltende esbl nachweisreagenzien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012. |